Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203592 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01203592: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01203592 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01203592, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of Albuterol at doses used in clinical practice.
Interventions
- DRUG Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01203592
The ClinicalTrials.gov registry entry for NCT01203592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Albuterol is the first listed.
NCT01203592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01203592 about?
NCT01203592 is a clinical study titled "Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes". The study tests the notion that patients suffering from certain types of congenital myasthenic syndromes are benefitted by the use of Albuterol at doses used in clinical practice.
What is the current status of trial NCT01203592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2010-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01203592?
The interventions under investigation include: Albuterol (DRUG).
Who is sponsoring clinical trial NCT01203592?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.